Anika Therapeutics, Inc. (ANIK) stock
ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$12.85−0.07 (-0.54%)
Close on Nov 17, 2026Market cap $171.97MP/E –Yield –
Anika Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Anika Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 62.2%. For fiscal 2025 it was 56.6%, against 63.4% the year before. The highest annual figure on record is 80.2% in fiscal 2014.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 56.6% | −6.8 |
| FY2024 | Dec 31, 2024 | 63.4% | −4.9 |
| FY2023 | Dec 31, 2023 | 68.3% | +4.0 |
| FY2022 | Dec 31, 2022 | 64.3% | +8.2 |
| FY2021 | Dec 31, 2021 | 56.1% | +3.2 |
| FY2020 | Dec 31, 2020 | 52.9% | −22.0 |
| FY2019 | Dec 31, 2019 | 74.9% | +4.6 |
| FY2018 | Dec 31, 2018 | 70.4% | −5.5 |
| FY2017 | Dec 31, 2017 | 75.9% | −0.9 |
| FY2016 | Dec 31, 2016 | 76.8% | −0.6 |
| FY2015 | Dec 31, 2015 | 77.4% | −2.8 |
| FY2014 | Dec 31, 2014 | 80.2% | +10.5 |
| FY2013 | Dec 31, 2013 | 69.7% | +10.3 |
| FY2012 | Dec 31, 2012 | 59.4% | +0.7 |
| FY2011 | Dec 31, 2011 | 58.7% | +1.5 |
| FY2010 | Dec 31, 2010 | 57.1% | −8.8 |
| FY2009 | Dec 31, 2009 | 65.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 65.1% | +14.2 |
| Q1 FY2026 | Mar 31, 2026 | 64.2% | +8.1 |
| Q4 FY2025 | Dec 31, 2025 | 62.6% | +6.7 |
| Q3 FY2025 | Sep 30, 2025 | 56.0% | −9.6 |
| Q2 FY2025 | Jun 30, 2025 | 50.9% | −15.8 |
| Q1 FY2025 | Mar 31, 2025 | 56.1% | −9.3 |
| Q4 FY2024 | Dec 31, 2024 | 56.0% | +42.5 |
| Q3 FY2024 | Sep 30, 2024 | 65.7% | +5.5 |
| Q2 FY2024 | Jun 30, 2024 | 66.7% | +1.3 |
| Q1 FY2024 | Mar 31, 2024 | 65.4% | +5.1 |
| Q4 FY2023 | Dec 31, 2023 | 13.4% | +3.9 |
| Q3 FY2023 | Sep 30, 2023 | 60.2% | +3.6 |
| Q2 FY2023 | Jun 30, 2023 | 65.4% | +2.7 |
| Q1 FY2023 | Mar 31, 2023 | 60.2% | +0.8 |
| Q4 FY2022 | Dec 31, 2022 | 9.5% | −41.1 |
| Q3 FY2022 | Sep 30, 2022 | 56.6% | −1.7 |
| Q2 FY2022 | Jun 30, 2022 | 62.7% | +8.1 |
| Q1 FY2022 | Mar 31, 2022 | 59.4% | −1.7 |
| Q4 FY2021 | Dec 31, 2021 | 50.6% | −0.6 |
| Q3 FY2021 | Sep 30, 2021 | 58.2% | +3.5 |
| Q2 FY2021 | Jun 30, 2021 | 54.6% | +9.8 |
| Q1 FY2021 | Mar 31, 2021 | 61.2% | +1.3 |
| Q4 FY2020 | Dec 31, 2020 | 51.2% | −19.7 |
| Q3 FY2020 | Sep 30, 2020 | 54.7% | −25.2 |
| Q2 FY2020 | Jun 30, 2020 | 44.8% | −32.7 |
| Q1 FY2020 | Mar 31, 2020 | 59.9% | −10.5 |
| Q4 FY2019 | Dec 31, 2019 | 70.9% | −3.1 |
| Q3 FY2019 | Sep 30, 2019 | 80.0% | +10.9 |
| Q2 FY2019 | Jun 30, 2019 | 77.5% | +4.2 |
| Q1 FY2019 | Mar 31, 2019 | 70.4% | +7.3 |
| Q4 FY2018 | Dec 31, 2018 | 74.0% | +5.4 |
| Q3 FY2018 | Sep 30, 2018 | 69.1% | −7.9 |
| Q2 FY2018 | Jun 30, 2018 | 73.3% | +7.5 |
| Q1 FY2018 | Mar 31, 2018 | 63.1% | −10.9 |
| Q4 FY2017 | Dec 31, 2017 | 68.6% | −3.6 |
| Q3 FY2017 | Sep 30, 2017 | 77.0% | −3.6 |
| Q2 FY2017 | Jun 30, 2017 | 65.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 74.0% | – |
| Q4 FY2016 | Dec 31, 2016 | 72.3% | – |
| Q3 FY2016 | Sep 30, 2016 | 80.6% | – |
See a number that looks wrong?